<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00903422</url>
  </required_header>
  <id_info>
    <org_study_id>112509</org_study_id>
    <nct_id>NCT00903422</nct_id>
  </id_info>
  <brief_title>Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)</brief_title>
  <official_title>Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of eltrombopag in the treatment of low
      platelet counts in adult subjects with advanced myelodysplastic syndrome (MDS), secondary
      acute myeloid leukemia after MDS (sAML/MDS), or de novo AML that are relapsed, refractory or
      ineligible to receive azacitidine, decitabine, intensive chemotherapy or
      autologous/allogeneic stem cell transplantation. This is a placebo-controlled study in which
      patients will receive study medication daily for 6 months, during which time the dose of
      study medication may be adjusted based upon individual platelet counts and bone marrow blast
      counts. All subjects will receive best standard of care (platelet transfusions, mild
      chemotherapy, cytokines, valproic acid, all-trans retinoic acid, ESAs or G-CSF) in addition
      to study medication. Subjects taking placebo may be allowed to crossover to eltrombopag
      treatment if a clinically and statistically significant improvement in bone marrow blast
      counts is seen in subjects treated with eltrombopag.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double-blind, randomized, placebo-controlled phase I/II study to evaluate the safety and
      tolerability of eltrombopag olamine, a thrombopoietin receptor agonist, administered for 6
      months as oral tablets once daily in adult subjects with advanced MDS, sAML/MDS, or de novo
      AML. Study medication may be increased up to 300 mg (150 mg maximum dose for East Asian
      subjects), based upon individual platelet counts and bone marrow blast counts.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 14, 2009</start_date>
  <completion_date type="Actual">December 5, 2013</completion_date>
  <primary_completion_date type="Actual">June 26, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability parameters including non-hematological laboratory Grade 3/Grade 4 toxicities, change in bone marrow blast counts from baseline and adverse events reporting.</measure>
    <time_frame>Approximately 46 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a baseline platelet count &lt;20 Gi/L and an increase to &gt;20 Gi/L and by at least 2x baseline; or a baseline platelet count between &gt;=20-&lt;30 Gi/L and an absolute platelet count increase to &gt;=50 Gi/L at any time during treatment.</measure>
    <time_frame>Approx. 46 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and number of units of platelet transfusions during the treatment and follow-up periods for eltrombopag- and placebo-treated subjects.</measure>
    <time_frame>approx 46 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of bleeding events, measured using the World Health Organization (WHO) Bleeding Scale, during the treatment and 4 week follow-up periods for eltrombopag- and placebo-treated subjects.</measure>
    <time_frame>approx. 46 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) of eltrombopag- and placebo-treated subjects.</measure>
    <time_frame>approx. 46 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of life as measured using the EQ-5D questionnaire.</measure>
    <time_frame>approx. 46 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Eltrombopag</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eltrombopag</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eltrombopag olamine</intervention_name>
    <description>thrombopoietin receptor agonist</description>
    <arm_group_label>Eltrombopag</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets with no active pharmaceutical ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (18 years of age or older) with advanced MDS, sAML/MDS, or de novo AML
             with &gt;=10% and &lt;=50% blasts in bone marrow. Peripheral blood blast change over time
             should not be suggestive of highly proliferative disease (as judged by the
             investigator).

          -  Subjects must be dependent on regular platelet transfusions or have a platelet count
             taken within the 4 weeks prior to randomization that is &lt;30 Gi/L.

          -  Subjects must be relapsed, refractory or ineligible to receive standard treatment
             options of azacitidine and decitabine and must be relapsed, refractory or ineligible
             to receive intensive chemotherapy or autologous/allogeneic stem cell transplantation.
             A subject may be considered relapsed/refractory to a standard treatment if it is
             discontinued due to lack of efficacy. For subjects ineligible for standard treatments,
             it is permissible to start one of these standard treatments while on study medication
             if the Investigator considers that the subject becomes eligible during the course of
             the study.

          -  Prior therapy with demethylating agents (azacitidine or decitabine), lenalidomide or
             IL-11(oprelvekin) must have been completed at least 4 weeks before Day 1;
             antithymocyte/antilymphocyte globulin, intensive chemotherapy, or
             autologous/allogeneic stem cell transplantation must have been completed at least 2
             months before Day 1. If a subject must discontinue a course of therapy due to lack of
             efficacy, the washout periods listed above do not apply (and the patient may be
             screened and randomized immediately if other eligibility criteria are met).

          -  Subjects must have platelet count and platelet transfusion data available over a
             period of 4 weeks prior to randomization.

          -  Subjects with advanced MDS, sAML/MDS, or de novo AML must have stable disease
             indicated by a doubling time of peripheral blast counts &gt;7 days during screening.

          -  During the 4 weeks prior to randomization, subjects must have a baseline bone marrow
             examination including the following:

          -  cytomorphology to confirm bone marrow blasts between 10-50%,

          -  cytogenetics (provide only most prevalent abnormal clone),

        The results of the above tests are required prior to subject randomization.

          -  Supportive/palliative therapies such as cytokines (except for IL-11; oprelvekin),
             valproic acid, all-trans retinoic acid or mild chemotherapy are allowed if part of the
             local SOC, provided those therapies have been at a stable dose for 4 weeks. If the
             subject chooses to discontinue these therapies prior to study entry, they must be
             completed 4 weeks prior to enrollment into this study, unless the therapy is
             discontinued due to lack of efficacy. Erythropoiesis-stimulating agents (ESAs) in
             anemic subjects or granulocyte colony-stimulating factor (G-CSF) in subjects with
             severe neutropenia and recurrent infections are allowed during the study as per
             accepted standards. Subjects who enter the study on ESAs or G-CSF should continue at
             the same dose schedule until the optimal dose of study medication has been
             established.

          -  ECOG Status 0-3.

          -  Subject is able to understand and comply with protocol requirements and instructions.

          -  Subject has signed and dated informed consent.

          -  Prothrombin time (PT/INR) and activated partial thromboplastin time (aPTT) must be
             within 80 to 120% of the normal range at baseline.

          -  Adequate baseline organ function defined by the criteria below:

          -  total bilirubin (except for Gilbert's Syndrome) &lt;= 1.5xULN

          -  ALT and AST &lt;= 3xULN

          -  creatinine &lt;= 2xULN

          -  albumin must not be below the lower limit of normal (LLN) by more than 20%.

          -  Subject is practicing an acceptable method of contraception (documented in chart).
             Female subjects (or female partners of male subjects) must either be of
             non-childbearing potential (hysterectomy, bilateral oophorectomy, bilateral tubal
             ligation or post-menopausal &gt;1 year), or of childbearing potential and use 1 of the
             following highly effective methods of contraception (i.e., Pearl Index &lt;1.0%) from 2
             weeks prior to administration of study medication, throughout the study, and 28 days
             after completion or premature discontinuation from the study:

          -  Complete abstinence from intercourse;

          -  Intrauterine device (IUD);

          -  Two forms of barrier contraception (diaphragm plus spermicide, and for males condom
             plus spermicide);

          -  Male partner is sterile prior to entry into the study and is the only partner of the
             female;

          -  Systemic contraceptives (combined or progesterone only).

        Exclusion Criteria:

          -  Subjects with a diagnosis of acute promyelocytic leukemia.

          -  History of treatment for cancer (other than MDS, sAML/MDS, or de novo AML) with
             systemic chemotherapy and/or radiotherapy within the last 2 years.

          -  History of treatment with romiplostim or other TPO-R agonists.

          -  Pre-existing cardiovascular disease (including congestive heart failure, New York
             Heart Association [NYHA] Grade III/IV), or arrhythmia known to increase the risk of
             thromboembolic events (e.g. atrial fibrillation), or subjects with a QTc &gt;450 msec
             (QTc &gt;480 msec for subjects with Bundle Branch Block).

          -  Bone marrow fibrosis that leads to an inability to aspirate marrow for assessment.

          -  Spleen size &gt;14 cm (length as per ultrasound examination).

          -  Leukocytosis &gt;=25,000/uL prior to Day 1 of study medication.

          -  Female subjects who are nursing or pregnant (positive serum or urine Beta-human
             chorionic gonadotropin [B-hCG] pregnancy test) at screening or pre-dose on Day 1.

          -  Current alcohol or drug abuse.

          -  Treatment with an investigational drug within 30 days or 5 half-lives (whichever is
             longer) preceding the first dose of study medication.

          -  Active and uncontrolled infections.

          -  Subjects infected with Hepatitis B, C or Human Immunodeficiency Virus (HIV).

          -  Subjects with liver cirrhosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salvador</city>
        <state>Bahía</state>
        <zip>41253-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20230 -130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koebenhavn Oe</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bayonne cedex</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Besançon cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bobigny Cedex</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Caen cedex 9</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reggio Calabria</city>
        <state>Calabria</state>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vicenza</city>
        <state>Veneto</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Puerto Rico</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/112509?search=study&amp;search_terms=112509#rs</url>
    <description>Results for study 112509 can be found on the GSK Clinical Study Register.</description>
  </link>
  <reference>
    <citation>Mavroudi I, Pyrovolaki K, Pavlaki K, Kozana A, Psyllaki M, Kalpadakis C, Pontikoglou C, Papadaki HA. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res. 2011 Mar;35(3):323-8. doi: 10.1016/j.leukres.2010.06.029. Epub 2010 Aug 4.</citation>
    <PMID>20688394</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2009</study_first_submitted>
  <study_first_submitted_qc>May 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2009</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Myelodysplastic Syndrome</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>sAML/MDS</keyword>
  <keyword>Eltrombopag</keyword>
  <keyword>TPO-R agonist</keyword>
  <keyword>de novo AML</keyword>
  <keyword>Thrombopoietin</keyword>
  <keyword>MDS</keyword>
  <keyword>Thrombopoietin receptor agonist</keyword>
  <keyword>secondary Acute Myeloid Leukemia after MDS</keyword>
  <keyword>Platelets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

